One Rare Metal, a $1.5B Bet on the Heart

Boston Scientific invests $1.5B in MiRus for a rhenium-alloy TAVR valve challenging the market's top players

1 Jun 2026

Aortic stenosis kills slowly. For the roughly five million Americans living with the condition, a catheter-delivered replacement valve has become the standard rescue. Two companies, Edwards Lifesciences and Medtronic, have long shared the spoils of that rescue. Boston Scientific, for now, watches from the side.

That position may not hold. On 18 May 2026, Boston Scientific announced a $1.5bn investment in MiRus, a startup whose transcatheter aortic valve replacement (TAVR) device, SIEGEL, is built from rhenium, a dense metallic element that appears nowhere else in the field. The deal gives Boston Scientific a 34% equity stake, plus an exclusive option to acquire MiRus's entire TAVR business for a further $3bn, contingent on clinical and regulatory targets.

The material choice is the argument. Virtually every competing valve relies on a nickel-titanium frame. SIEGEL's rhenium frame is coated with nitric oxide and delivers radial strength that its makers claim exceeds cobalt or titanium alternatives. An open-cell design avoids foreshortening, a deployment behavior associated with higher pacemaker implantation rates in current devices. Delivery through an 8 French sheath, roughly half the profile of rival systems, may reduce vascular complications and expand the treatable pool of patients.

Caution is built into the timeline. SIEGEL carries no commercial approval anywhere. Enrollment in the STAR trial, a randomized controlled study targeting up to 1,025 patients across low, intermediate, and high surgical risk profiles, began only in April 2026. BTIG analysts have noted that any earnings impact for Boston Scientific in 2026 will be immaterial. Rhenium's manufacturing scalability at commercial volumes remains untested.

Patience, then, is what this bet actually costs. Capital is committed; outcomes are not. Should SIEGEL clear its milestones, operating rooms would gain a smaller sheath, more precise valve placement, and potentially fewer post-procedural pacemakers. Boston Scientific is wagering that the next competitive edge in structural heart therapy will come from materials science, not from refining what already exists.